Skip to main
  1. Stocks
  2. Nanobiotix SA
  3. Forecast
NBTX

Nanobiotix SA (NBTX) Stock Forecast & Price Target

Nanobiotix SA (NBTX) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Nanobiotix is viewed favorably because its lead asset NBTXR3 has already shown clinical proof-of-concept in Phase 1/2 studies, including a more than doubling of pathological complete response in soft tissue sarcoma versus radiation alone, while also benefiting from a 2023 partnership that transferred global rights and brought up to $1.8Bn in milestones plus tiered royalties. Its first pivotal catalyst, NANORAY-312 in chemo-ineligible LA-HNSCC, is considered high probability of success and could validate a tumor-agnostic, physics-based mechanism that fits seamlessly into existing radiotherapy practice, with supportive data also emerging in Stage III NSCLC through CONVERGE. Financially, the company ended 1Q26 with €42.1M in cash and equivalents and a runway into 2029, reducing near-term funding risk while it advances multiple large-market opportunities.

Bears say

Nanobiotix is exposed to substantial clinical, regulatory, commercial, and intellectual property risk, with a high likelihood that trial failures, safety concerns, or regulatory setbacks could derail value creation across its novel pipeline. The company also faces execution and financial strain, as meaningful debt on the balance sheet and the need for additional funding before turning cash flow positive raise the risk of potentially dilutive financing and spending overruns. Further, the outlook is weakened by uncertainty around undisclosed collaboration milestones and the possibility that post-approval commercial performance falls below expectations, especially for a highly novel lead program that may face logistical challenges.

Nanobiotix SA (NBTX) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nanobiotix SA and is not a guaranteed prediction by Public.com or investment advice.

Nanobiotix SA (NBTX) Analyst Forecast & Price Prediction

Get the latest Nanobiotix SA (NBTX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Nanobiotix SA (NBTX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nanobiotix SA (NBTX) Forecast

Analysts have given Nanobiotix SA (NBTX) a Buy based on their latest research and market trends.

According to 3 analysts, Nanobiotix SA (NBTX) has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nanobiotix SA (NBTX)


Nanobiotix SA (NBTX) Analyst Forecast & Price Prediction

Get the latest Nanobiotix SA (NBTX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Nanobiotix SA (NBTX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover NBTX stock data and trends